Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Remedy Q1'25 flash comment: Good start to the year ahead of FBC: Firebreak release

By Atte RiikolaAnalyst
Remedy Entertainment

Translation: Original published in Finnish on 04/30/2025 at 09:25 am EEST Remedy300425Remedy reported clearly better-than-expected Q1 earnings this morning. There were more development fees than we expected in Q1, and the company's cost structure was also lighter than we expected. Alan Wake 2’s royalties evolved in line with our expectations, and the game continues to generate stable sales, according to the company. All game projects have progressed at a good pace in Q1 according to the compay and FBC: Firebreak's release (June 17) is already around the corner. Overall, the Q1 report was an encouraging start to the year, as our earnings expectations have focused on the end of the year for 2025.

Revenue exceeded our expectations in terms of development fees

Remedy’s Q1 revenue grew by 24% to 13.4 MEUR which exceeded our 11.6 MEUR estimate. As expected, development fees (Q1'25: 10.7 MEUR) accounted for most of revenue, but more of them were recognized as revenue in Q1 than we had expected. We believe most development fees came from the Max Payne subcontracting project that was in production. Control 2, which entered full production in February, has apparently also generated more development fees than we expected (Annapurna finances 50% of the estimated production budget of around 50 MEUR).

Royalties in Q1 were 2.6 MEUR, which was exactly what we expected. According to Remedy, most of these were related to Alan Wake 2 royalties, which was what we expected. According to the company, Alan Wake 2 continues to sell steadily and accumulate royalties. At the turn of last year, the game's sales exceeded 2 million copies, but the figure was not updated at this point.

Q1 earnings clearly better than our estimates

In Q1, Remedy’s EBITDA was 2.6 MEUR (Q1’24 -1.2 MEUR), exceeding our forecast of -0.9 MEUR clearly. Due to the fixed cost structure, the revenue overshoot is reflected directly in earnings lines, and the cost structure was overall lighter than we predicted in Q1. In particular, outsourcing costs were lower than expected in Q1. In our estimates, Remedy’s earnings expectations are focused on H2 this year, as  FBC: Firebreak to be released on June 17, starts to generate revenue for the company. Relative to this, the development in Q1 was promising.

As expected, outlook remains unchanged at this point of the year

In its guidance, Remedy estimates revenue (2024: 50.7 MEUR) and EBIT (-4.3 MEUR) to increase compared to the previous year and that EBIT will be positive. The focus for growth is naturally on the release of FBC: Firebreak, but in addition, the royalties from Alan Wake 2 and other older games create a base for revenue. Remedy has strengthened its self-publishing team to best support sales of already released older games in digital channels. The Max Payne project and Control 2 will continue to generate significant development fees this year. Our forecast before the report expected revenue of 65.8 MEUR (+30%) and EBIT of 1.7 MEUR for this year. With the earnings overshoot in Q1, there is some upside pressure in the estimates. In the big picture, medium-term performance expectations are weighted towards 2027, when Control 2 is very likely to be released.

 

Login required

This content is only available for logged in users

Create account

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures13.02.

202425e26e
Revenue50.765.871.9
growth-%49.3 %29.9 %9.2 %
EBIT (adj.)-4.31.72.4
EBIT-% (adj.)-8.4 %2.6 %3.3 %
EPS (adj.)-0.270.100.14
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.164.6119.3
EV/EBITDA65.925.016.5

Forum discussions

Great trailer and the hype started nicely. Hopefully, the Remedyverse is hammered with a customizable sledgehammer into the black hole at the...
10 hours ago
by T4K1_
3
I will probably play this. Like most Remedy games. But compared to my expectations, the predominant feeling was disappointment. Perhaps most...
12 hours ago
by 1sarvinen
9
In my opinion, this doesn’t really matter to an investor whether the game is ultimately good or not. The hype train has now started big time...
13 hours ago
by Pohjolan Eka
22
Yes, the hype from Asmongold (4+ million followers) and other big YouTubers/social media influencers really does have an effect on generating...
16 hours ago
by amoult
9
Even Asmongold praised the trailer, so it can only be top-notch But seriously, it certainly looks good, and gameplay will surely determine its...
17 hours ago
by marmot76
8
That trailer was really nice to watch. It seems to have already gathered a lot of viewers and positive comments
18 hours ago
by Zesvel
7
That was indeed a great first trailer. You can immediately see that these main games are what Remedy truly invests in, and then there are the...
18 hours ago
by Wappie
10
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.